Study #2022-0431
A phase II study of neoadjuvant sacituzumab govitecan and pembrolizumab therapy for immunochemotherapy-resistant early-stage triple-negative breast cancer (TNBC)
MD Anderson Study Status
Enrolling
Treatment Agent
Sacituzumab Govitecan, Pembrolizumab
Description
To learn if sacituzumab govitecan and pembrolizumab, when given before surgery, can help to control early-stage triple negative breast cancer that has not responded well to other treatments.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Breast Cancer
Study phase:
Phase II
Physician name:
Clinton Yam
Department:
Breast Medical Oncology
For general questions about clinical trials:
1-855-479-2433
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.